

Press Releases

All Years

[Advanced Search](#)

MAY 9, 2023

[Perrigo Reports First Quarter Fiscal Year 2023 Financial Results From Continuing Operations](#)

MAY 9, 2023

[Perrigo Announces Chief Executive Officer Retirement and Succession Plan](#)

MAY 4, 2023

[PERRIGO ANNOUNCES QUARTERLY DIVIDEND](#)

APR 25, 2023

[Perrigo to Release First Quarter 2023 Financial Results on May 9, 2023](#)

MAR 28, 2023

[Perrigo Announces New Date for Joint FDA Advisory Committee Meeting to Review Opill® Daily Oral Contraceptive for OTC Use](#)



MAR 17, 2023

[Perrigo Announces Voluntary Recall of Limited Quantity of Gerber® Good Start® SoothePro™ Powdered Infant](#)



[Formula](#)

 [Photos \(1\)](#)

MAR 2, 2023

[**Perrigo to Present at Upcoming 12th Annual UBS Global Consumer and Retail Conference**](#)



MAR 1, 2023

[**Perrigo Announces FDA Approval of the Store Brand OTC Equivalent of Advil® Dual Action Tablets**](#)

 [Photos \(1\)](#)

FEB 28, 2023

[**Perrigo Launches its 3-Year Optimize and Accelerate Strategic Plan, Issues Fiscal 2023 Guidance and Introduces 2025 Financial Targets at Investor Day**](#)

FEB 27, 2023

[**Perrigo Reports Fourth Quarter & Fiscal Year 2022 Financial Results From Continuing Operations**](#)

FEB 21, 2023

[**Perrigo Increases its Quarterly Dividend**](#)

FEB 14, 2023

[**Perrigo to Release Fourth Quarter and Fiscal Year 2022 Financial Results on February 27, 2023, Conduct Virtual Investor Day on February 28, 2023**](#)

DEC 19, 2022

[Perrigo to Host Virtual Investor Day on February 28, 2023](#)

NOV 8, 2022

[Perrigo Reports Third Quarter Fiscal Year 2022 Financial Results From Continuing Operations](#)

NOV 3, 2022

[Perrigo Announces Quarterly Dividend](#)



NOV 1, 2022

[Perrigo Announces Strategic Investment to Expand and Strengthen U.S. Manufacturing of Infant Formula](#)

 [Photos \(1\)](#)

OCT 26, 2022

[Perrigo Receives Notification of Postponement for Joint FDA Advisory Committee to Review Opill® Daily Oral Contraceptive for Over-The-Counter \(OTC\) Use](#)

OCT 25, 2022

[Perrigo to Release Third Quarter 2022 Financial Results on November 8, 2022](#)

SEP 12, 2022

[PERRIGO ANNOUNCES JOINT FDA ADVISORY COMMITTEE TO REVIEW OPILL® DAILY ORAL CONTRACEPTIVE FOR OVER-THE-COUNTER \(OTC\) USE](#)

AUG 17, 2022

[PERRIGO RELEASES STATEMENT ON RECENT MARKET TRADING ACTIVITY](#)

AUG 9, 2022

[PERRIGO REPORTS SECOND QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS](#)

AUG 2, 2022

[PERRIGO ANNOUNCES QUARTERLY DIVIDEND](#)

JUL 27, 2022

[PERRIGO TO RELEASE SECOND QUARTER 2022 FINANCIAL RESULTS ON AUGUST 9, 2022](#)

JUL 11, 2022

[Perrigo's HRA Pharma Submits Application to FDA for First-Ever OTC Birth Control Pill](#)

JUN 1, 2022

[PERRIGO PROMOTES ALISON IVES TO ROLE OF CHIEF SCIENTIFIC OFFICER](#)

Show per page

[«](#) [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [...](#) [38](#) [»](#)

